Navigation Links
Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Date:11/5/2007

- Results demonstrated 17% overall rate of sustained virologic response in

non-responders to previous interferon-based therapy - - SVR results in line with previous studies of long-acting interferons in

non- responders, with less frequent dosing - - Final data from Phase 2 Albuferon non-responder study presented at the Annual Meeting of the American Association for the Study of Liver Diseases

(AASLD) -

ROCKVILLE, Ma., Nov. 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final results of a Phase 2 trial of the investigational drug, Albuferon(R) (albinterferon alfa-2b), in combination with ribavirin in patients with chronic hepatitis C who failed to respond to previous interferon-based therapy. The results were presented yesterday in Boston at the 58th AASLD Annual Meeting in Boston.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"The results of the Albuferon non-responder study demonstrated that Albuferon treatment at doses up to 1800 mcg every two weeks had an acceptable long-term safety profile and produced an overall sustained virologic response (SVR) rate of 17% in these patients," said David Nelson, M.D., Associate Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section, University of Florida. "In the difficult to treat subgroup of genotype 1 chronic hepatitis C patients who previously failed to respond to treatment with pegylated interferon and ribavirin, Albuferon treatment produced an overall SVR rate of 11%."

In the open-label,
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... 2015 , ... Displays and Exhibits , a top online retailer of ... all purchases that include branding. Enter price code brand2015 for a ten percent discount ... packaging and promotional materials, all should integrate the company logo to communicate the brand. ...
(Date:6/29/2015)... Wethersfield, CT (PRWEB) , ... June 29, 2015 ... ... their centers recognized by the independent auditor of customer service for the 40-center ... of more than 1,100 skilled nursing centers in the United States in one ...
(Date:6/29/2015)... ... June 29, 2015 , ... Assurex Health, a precision medicine ... and chronic pain conditions, has announced appointments to three key leadership roles, according ... Senior Vice President, Chief Financial Officer; Craig S. Lewis, Senior Vice President, Chief ...
(Date:6/29/2015)... ... June 29, 2015 , ... New ... that fewer than 10 percent of U.S. state and local governments have implemented ... an implementation deadline for NG9-1-1. , “Mobile phones have surpassed land lines ...
(Date:6/29/2015)... ... 29, 2015 , ... Blue Cross and Blue Shield of ... Markets division, which includes the company’s commercial health plan portfolio of products and ... and international reach. Mary Ellen Anderson now holds the title of vice president, ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3
... http://healthworldnet.com ) receives three Standard of Excellence awards,from ... of,outstanding web sites., The awards were given ... Excellence, and Portal Standard of Excellence. "We are ... CEO of Health,WorldNet, Inc. "The site has only ...
... Medical,Technologies, Inc. (Nasdaq: PMTI ), a leading ... today announced financial,results for the third quarter ended ... 30, 2008 were $24.2 million, of which $19.2 ... $1.0 million,were funded development revenues, and $1.25 million ...
... Mid-Atlantic Region, ATLANTA, Oct. 30 AmeriCare ( ... the opening of its,latest franchises serving Howard, Montgomery, and ... states in the union, Maryland is in the,top 20 ... Marylanders is over the,age of 60. AmeriCare of Maryland ...
... The American Fertility Association,introduces Manicures and Martinis, a ... together in a casual setting over manicures and,martinis ... fertility. It,s,free, relaxing, fun, and educational. The series ... by leading professionals in the reproductive medical,field, including ...
... China Sky One,Medical, Inc. ("China Sky One Medical" ... fully integrated pharmaceutical company producing over-the-counter,drugs in the ... it,recently obtained production approval from the State Food ... its newly developed drugs., Sodium ferulate by ...
... N.J., Oct. 30 Orchid Cellmark Inc.,(Nasdaq: ORCH ), ... its financial results for the third quarter of,2008., Total ... to $15.6 million for the third quarter of 2007. The ... to a year ago was,largely due to lower revenues in ...
Cached Medicine News:Health News:HealthWorldNet.com Receives Three Excellence Awards 2Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 2Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 4Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 5Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 6Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 7Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 8Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 9Health News:Caregiving Company AmeriCare Adds Franchise in Maryland 2Health News:The American Fertility Association Announces Plan to Help Young Women Preserve Fertility 2Health News:China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 2Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 8
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: